Anupam Rasayan signs MoU with 3xper Innoventure for new age pharma molecules

The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models

Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030

Intent to start at least 5 innovative Phase 3 vaccine programs by 2025

VitaDAO launches VITA-FAST tokens, revolutionizing governance in longevity research

The VITA-FAST tokens have been met with overwhelming interest

Merck to expand reagent production capacity in China

The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons

Meissa Vaccines enters into CGMP manufacturing agreement for pediatric RSV vaccine candidate for Phase 2 clinical trials

Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials

Lonza collaborates with Vertex on cell, gene technologies manufacturing

Under the terms of the collaboration, Vertex and Lonza will partner in the process development and scale-up for the manufacturing of the product portfolio and co-invest to build a dedicated new facility in Portsmouth, New Hampshire (US)

Ashland announces Polyplasdone Plus multifunctional disintegrant for improved pharmaceutical process

This innovative product eliminates two manufacturing steps and simplifies equipment setup

Industry needs to establish a self-regulatory body to maintain the quality of the pharma products, says Dr Mandaviya

Natural Capsules announces strategic investment by Somerset Indus Capital Partners

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth